[{"id":"e287b7f7-e014-48e2-9282-b4b1f1b1dc60","acronym":"","url":"https://clinicaltrials.gov/study/NCT03513952","created_at":"2021-01-18T17:17:53.265Z","updated_at":"2024-07-02T16:35:26.918Z","phase":"Phase 2","brief_title":"Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma","source_id_and_acronym":"NCT03513952","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • IFNG • CD4","pipe":" | ","alterations":" PD-L1 expression • IFNG expression","tags":["PD-L1 • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • IFNG expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • CYT107"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 06/05/2019","start_date":" 06/05/2019","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 10/22/2024","study_completion_date":" 10/22/2024","last_update_posted":"2023-12-06"},{"id":"be0663b5-2478-4403-8fcb-c2a5b443dd4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01881867","created_at":"2021-01-18T08:26:13.034Z","updated_at":"2024-07-02T16:36:58.281Z","phase":"Phase 2","brief_title":"CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT01881867","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" IFNG • CSF2 • PSAP","pipe":"","alterations":" ","tags":["IFNG • CSF2 • PSAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CYT107"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 09/10/2013","start_date":" 09/10/2013","primary_txt":" Primary completion: 05/15/2017","primary_completion_date":" 05/15/2017","study_txt":" Completion: 01/02/2018","study_completion_date":" 01/02/2018","last_update_posted":"2019-07-09"}]